AngioDynamics (ANGO) AI Stock Analysis

• Market Cap: $479.57M
• Dividend Yield: N/A
• Average Volume (3M): 514.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: 2.73%
• EPS Growth: 87.03%
• Country: US
• Employees: 748
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.10
• Shares Outstanding: 41,199,844
• 10 Day Avg. Volume: 763,909
• 30 Day Avg. Volume: 514,232
• PEG Ratio: 0.15
• Price to Book (P/B): 2.28
• Price to Sales (P/S): 1.43
• P/FCF Ratio: -27.37
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 1.29
• Enterprise Value/Gross Profit: 2.50
• Enterprise Value/Ebitda: -50.97
• 1Y Price Target: $17.63
• Price Target Upside: 51.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 61 Neutral
• Price Target: $12.50 ▲(7.39% Upside)

AngioDynamics' overall stock score reflects a mixed outlook. The most significant factor is the company's financial performance, which is challenged by negative profitability and cash flow issues. However, the technical analysis shows strong momentum, and the positive earnings call with increased guidance provides optimism for future performance. Valuation concerns remain due to the negative P/E ratio and lack of dividend yield.

Positive Factors

Revenue Growth

AngioDynamics' consistent revenue growth, particularly in the MedTech segment, reflects strong market demand and effective product positioning, supporting long-term business expansion.

Cash Position

A strong cash position enhances AngioDynamics' ability to invest in growth opportunities, manage debt, and navigate economic uncertainties, supporting long-term financial stability.

Guidance Increase

Raising guidance indicates management's confidence in AngioDynamics' strategic initiatives and market opportunities, suggesting sustained growth and profitability improvements.

Negative Factors

Profitability Challenges

Ongoing profitability issues, reflected in negative margins, highlight operational inefficiencies that could hinder AngioDynamics' ability to generate sustainable earnings long-term.

Cash Flow Issues

Negative cash flow indicates potential liquidity constraints, limiting AngioDynamics' capacity to fund operations and invest in growth, impacting long-term financial health.

NanoKnife Reimbursement Challenges

Delays in NanoKnife reimbursement could slow adoption and revenue growth in this segment, affecting AngioDynamics' ability to capitalize on this technology in the near term.

AngioDynamics Business Overview & Revenue Model

Company Description

AngioDynamics, Inc. is a medical device company that specializes in innovative products for the minimally invasive treatment of various medical conditions. The company operates primarily in the vascular access, peripheral vascular, and oncology markets, offering a range of products including vascular access devices, ablation systems, and drainage systems. AngioDynamics is dedicated to improving patient outcomes through its advanced technologies and solutions designed for use in hospitals and outpatient settings.

How the Company Makes Money

AngioDynamics generates revenue through multiple key streams primarily centered around the sale of its medical device products. The company's main revenue sources include vascular access products, which provide healthcare professionals with the tools necessary for catheter placement and administration of medications; ablation systems used for the treatment of tumors and other conditions; and drainage systems designed for effective fluid management. Furthermore, AngioDynamics benefits from recurring revenue through the sale of consumable supplies and accessories that accompany its devices. The company also engages in partnerships with healthcare providers and distributors to enhance market reach and customer access, thereby contributing to its earnings. Additionally, AngioDynamics may explore collaborations with other medical technology firms to expand its product offerings and entry into new markets, further enhancing its revenue potential.

AngioDynamics Financial Statement Overview

Summary

AngioDynamics faces significant financial hurdles, with declining revenues, persistent losses, and cash flow difficulties. While leverage is low, the company needs to address profitability and cash generation to improve its financial health and support future growth.

Income Statement

AngioDynamics shows a declining revenue trend over recent years, with the latest TTM revenue at $283.32M, down from $303.91M in 2024. The gross profit margin remains stable at around 53%, but the company struggles with profitability, reflected in significant negative EBIT and net income margins. The net loss has increased to $41.39M in TTM, showing a concerning trajectory.

Balance Sheet

The balance sheet displays moderate stability with a low debt-to-equity ratio of 0.03 in TTM, indicating minimal leverage. However, the equity ratio has decreased from 64% in 2023 to 65% in TTM, reflecting reduced shareholder equity. Despite a decline in total assets, the company maintains a healthy cash position.

Cash Flow

Cash flow analysis reveals challenges, as AngioDynamics reports negative operating and free cash flows. Although the free cash flow deficit has slightly reduced, the negative operating cash flow suggests cash management issues. The company's ability to convert net income to cash flow remains weak.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	300.72M	292.50M	303.91M	338.75M	316.22M	291.01M
Gross Profit	155.09M	157.71M	154.70M	174.25M	165.73M	156.79M
EBITDA	-7.60M	-1.66M	-6.13M	12.19M	11.13M	-8.90M
Net Income	-32.10M	-33.99M	-184.35M	-52.44M	-26.55M	-31.55M
Balance Sheet
Total Assets	265.64M	280.14M	317.67M	532.64M	552.75M	561.44M
Cash, Cash Equivalents and Short-Term Investments	38.76M	55.89M	76.06M	44.62M	28.82M	48.16M
Total Debt	0.00	3.95M	5.91M	55.06M	32.26M	20.00M
Total Liabilities	86.79M	97.17M	112.08M	154.34M	128.26M	121.98M
Stockholders Equity	178.85M	182.97M	205.59M	378.30M	424.49M	439.46M
Cash Flow
Free Cash Flow	-11.26M	-15.27M	-33.93M	-4.27M	-11.49M	10.38M
Operating Cash Flow	-8.47M	-10.81M	-28.16M	78.00K	-7.19M	24.09M
Investing Cash Flow	-9.32M	-10.18M	123.72M	-9.75M	-19.31M	-13.71M
Financing Cash Flow	1.08M	425.00K	-64.25M	25.42M	7.68M	-16.99M

AngioDynamics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Positive. The current price of 11.64 is above the 20-day moving average (MA) of 10.90, above the 50-day MA of 9.92, and above the 200-day MA of 9.94, indicating a bullish trend. The MACD of 0.36 indicates Negative momentum. The RSI at 70.64 is Negative, neither overbought nor oversold. The STOCH value of 56.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANGO.

AngioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	77 Outperform	$202.92M	16.93	10.39%	1.93%	-16.64%	-13.64%
INFU	70 Outperform	$211.61M	43.68	9.39%	―	8.13%	1293.06%
STXS	66 Neutral	$285.96M	―	-198.62%	―	33.94%	-6.91%
ANGO	61 Neutral	$479.57M	―	-17.10%	―	2.73%	87.03%
SMTI	53 Neutral	$277.66M	―	-25.78%	―	34.29%	-49.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	50 Neutral	$232.58M	25.27	-12.65%	―	-49.35%	-285.61%

AngioDynamics Corporate Events

AngioDynamics Secures $25M Credit Facility with JPMorgan

On May 28, 2025, AngioDynamics, Inc. entered into a new Credit Agreement with JPMorgan Chase Bank, N.A., securing a $25 million revolving credit facility. This agreement is intended to provide financial flexibility for the company during its manufacturing transfer process, supporting its strategic growth without impacting its operations. The facility includes a maturity date of May 28, 2027, and is secured by the company’s assets, with specific financial covenants and guarantees from its subsidiary, RITA Medical Systems, LLC.

The most recent analyst rating on (ANGO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.